Business
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
Promising reductions in rate of VOCs/SCPCs observed in monotherapy IMR-687 treated patients vs. placebo Biomarker data from both monotherapy IMR-687 and
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":"Promising reductions in rate of VOCs/SCPCs observed in monotherapy IMR-687 treated patients vs. placebo Biomarker data from both monotherapy IMR-687 and combination IMR-687+HU groups show improvement in markers of hemolysis with variable HbF results Reductions in hsCRP and NTproBNP in monotherapy IMR-687 treated patients suggest potential for lowering inflammation and cardiac stress in SCD IMR-687 was well tolerated as a monotherapy and in combination with hydroxyurea Additional data from Phase 2a open label extension trial and interim results from Ardent and Forte Phase 2b clinical trials expected in 2021 BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin (Hb), today reported results from its Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease (SCD). “I am encouraged by the incremental data from this readout, especially in light of the COVID-19 pandemic challenges,” said Biree Andemariam, M.D., Associate Professor at UConn School of Medicine, Director of the New England Sickle Cell Institute at UConn Health and lead investigator for the Phase 2a trial. “This includes a favorable safety profile of IMR-687, lower rate of VOCs/SCPCs and VOC-related hospitalizations in the Population A1 monotherapy arm and improvements in several biomarker results across both the monotherapy and combination groups. I am also pleased by the reductions in hsCRP and NT-proBNP in the Population A1 monotherapy arm. Both are clinically utilized biomarkers of inflammation and cardiac stress, respectively, and suggest that higher doses of IMR-687 may have novel anti-inflammatory and cardiovascular benefits in sickle cell disease.” “I would like to thank the patients, sickle cell disease community, and healthcare providers for their participation in this trial, particularly because the COVID-19 pandemic reduced access to clinical centers,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “These incremental Phase 2a results start an important year of data readouts at Imara. In the first quarter of 2021, we plan to report updates from our Phase 2a open label extension trial, including results on 10-15 patient...